
Press Release**DIASORIN LAUNCHES THE NEW LIAISON ANDROSTENEDIONE TEST FOR THE EVALUATION OF ADRENAL AND GONADAL FUNCTIONALITY**

May 16, 2017 - Saluggia (VC) - DiaSorin (FTSE Italy Mid Cap: DIA) is pleased to announce the launch of the new LIAISON test for the determination of Androstenedione in human serum and plasma, available worldwide with the exception of the U.S.

The Androstenedione, produced by the adrenal glands and by the ovaries and the testicles, is a hormone responsible for the onset of sexual differentiation and for stimulating the development of male secondary physical characteristics, such as a deep voice and facial hair. Particularly, elevated Androstenedione levels can be associated to male physical characteristics (virilization) in young girls.

Additionally, elevated Androstenedione levels in blood are associated with hormone-related diseases such as polycystic ovarian syndrome (PCOS), congenital adrenal hyperplasia (CAH) and adrenal gland tumors.

The new LIAISON® Androstenedione test expands the Company Fertility panel on CLIA technology and it is being recognized as the fastest assay available on the market.

The European infertility market is estimated at 130 million euros¹ with the Androstenedione accounting for about 2%², equal to a volume exceeding 1.5 million tests per year.

Francesco Colotta, *Chief Medical Officer of DiaSorin*, commented: *"We are continuously extending the number of products available on our LIAISON® platforms. The Androstenedione assay is a fully automated test capable of providing reliable results in 20 minutes; this cutting-edge instrument provides an accurate and timely diagnosis of a range of fertility-related disorders and aims at improving the effectiveness of treatments"*.

About DiaSorin

Headquartered in Italy and listed in the FTSE Italia Mid Cap Index, DiaSorin is a global leader in the In Vitro Diagnostics (IVD) field. For over 40 years the Company has been developing, producing and marketing reagent kits for IVD worldwide. Through constant investments in research and development, and using its own distinctive expertise in the field of immunodiagnosics to deliver a high level of innovation, DiaSorin offers today the broadest range of specialty tests available in the immunodiagnosics market and new tests in the molecular diagnostics markets, which identify DiaSorin Group as the IVD "diagnostics specialist".

For additional information, please contact:**Riccardo Fava**

Investor Relations & Corporate Communication Senior Director

Tel: +39.0161.487988

riccardo.fava@diasorin.it**Ines Di Terlizzi**

Investor Relator

Tel: +39.0161.487567

ines.diterlizzi@diasorin.it

¹ Source: EDMA

² Source: EDMA, including Italy, Germany and Spain